ROIV Latest Headlines

Analysts Conflicted on These Healthcare Names: Roivant Sciences (ROIV) and 4D Molecular Therapeutics (FDMT)

at www.tipranks.com (Thu, 22-Oct 6:00 AM)

Roivant jumps after Phase 3 NIU data show brepocitinib pushed median time-to-failure past 48 weeks

Market Chameleon (Wed, 21-Oct 10:47 AM)

Roivant (ROIV) sets Nov. 9 results call and Dec. 9 investor day, putting near-term focus on updates for LISRAYA, IMVT-1402, and mosliciguat

Market Chameleon (Wed, 21-Oct 7:44 AM)

Analysts Conflicted on These Healthcare Names: Roivant Sciences (ROIV), Alnylam Pharma (ALNY) and Haemonetics (HAE)

at www.tipranks.com (Wed, 21-Oct 12:40 PM)

Roivant to seek label expansion for Lisraya in uveitis after late-stage trial win

at seekingalpha.com (Wed, 21-Oct 9:23 AM)

Roivant reports strong Phase 3 data in uveitis

at www.tipranks.com (Wed, 21-Oct 7:29 AM)